H.C. Wainwright analyst Emily Bodnar downgraded Context Therapeutics to Neutral from Buy without a price target after the company said it is discontinuing development of its lead asset, Onaxr, and focusing resources on CTIM-76. The analyst views the news as disappointing given efficacy data in the OATH study "were encouraging." The firm says Context no longer has any clinical programs.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CNTX:
- Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
- Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
- Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
- Context Therapeutics highlights clinical responses from Phase 2 OATH trial
- Context Therapeutics Stock Soars on FDA Approval
